NICE TAs

27/03/2024

TA959: Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis

27/03/2024

TA958: Ritlecitinib for treating severe alopecia areata in people 12 years and over

21/02/2024

TA952: Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations

13/12/2023

TA939: Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer

22/11/2023

TA931: Zanubrutinib for treating chronic lymphocytic leukaemia

11/10/2023

TA918: Bimekizumab for treating axial spondyloarthritis

15/08/2023

TA912: Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease

28/04/2022

TA787: Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable

28/04/2022

TA786: Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies

11/10/2021

TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies

11/10/2021

TA705: Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer

11/10/2021

TA706: Ozanimod for treating relapsing–remitting multiple sclerosis

11/10/2021

TA707: Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer

11/10/2021

TA708: Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis

11/10/2021

TA710: Ravulizumab for treating atypical haemolytic uraemic syndrome

11/10/2021

TA709: Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency

11/10/2021

TA713: Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy

11/10/2021

TA712: Enzalutamide for treating hormone-sensitive metastatic prostate cancer

11/10/2021

TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed

11/10/2021

TA718: Ixekizumab for treating axial spondyloarthritis